Benzinga··Nabaparna BhattacharyaEsperion Acquires Enbumyst Maker Corstasis for $75M in Cash-Plus-Milestone Deal
Esperion acquires Corstasis for $75M upfront plus $180M in milestones, gaining FDA-approved nasal spray diuretic Enbumyst for heart failure treatment.
ESPRacquisitionFDA-approved